Tricyclic compounds as anticancer agents

Patent metadata

Field	Value
Publication number	US-9458156-B2
Application number	US-201414580355-A
Country	US
Kind code	B2
Filing date	Dec 23, 2014
Priority date	Dec 23, 2014
Publication date	Oct 4, 2016
Grant date	Oct 4, 2016

Abstract

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

First claim

What is claimed is:

1. A compound of the formula

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

2. A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

3. A method of treating cancer comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, multiple myeloma or AML.

Assignees

• Bristol Myers Squibb Co

Inventors

• Norris Derek J
• Delucca George V
• Gavai Ashvinikumar V
• Lee Francis Y
• Tokarski John S

Classifications

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title